Trials / Not Yet Recruiting

Not Yet RecruitingNCT06405243

Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients

The Combination of Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients

Status: Not Yet Recruiting
Phase: Phase 3
Study type: Interventional
Enrollment: 100 (estimated)

Sponsor: Beni-Suef University · Academic / Other
Sex: Female
Age: 20 Years – 40 Years
Healthy volunteers: Not accepted

Summary

The aim of the study is to compare and assess the efficacy of combined letrozole with myoinositol, chromium, or L-arginine in infertile women with PCOS. This study will help in the investigation of alternative therapeutic modalities for fertility improvement in polycystic ovarian syndrome

Detailed description

d prospective Study Trial. We will recruit patients diagnosed with PCOS according to Rotterdam criteria of PCOS and who present to outpatient clinics at Beni-Suef University Hospital. Infertile women will be randomized to receive letrozole (2.5 mg for 5 days from 3rd day of patients' menstrual cycle) combination with myoinositol, chromium or L-arginine

Conditions

Polycystic Ovary Syndrome

Interventions

Type	Name	Description
DRUG	Myoinositol	Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile
DRUG	Chromium	chromium picolinate may potentiates the therapeutic effect of letrozol on pituitary hormones (FSH and LH), improvement of ovulation, normalization of Estrogen level, improvement of endometrial thickness related to ovulation
DRUG	l-arginine	new antioxidant that minimizes the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO
DRUG	Letrozole 2.5mg	selective aromatase inhibitor

Timeline

Start date: 2024-06-30
Primary completion: 2024-12-31
Completion: 2024-12-31
First posted: 2024-05-08
Last updated: 2024-05-08

Locations

2 sites across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06405243. Inclusion in this directory is not an endorsement.